MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler’s 37th Annual Healthcare Conference. TELA’s management is scheduled to present at Piper Sandler’s 37th Annual Healthcare Conference at 2:30 pm ET on December 3rd, 2025. Interested parties can access the live and archived webcast at ir.telabio.com. Ab ...

Core Insights - Several small-cap biotech and therapeutics companies experienced significant gains in after-hours trading, driven by earnings updates, financial guidance, and regulatory developments [1] Company Summaries - Inotiv, Inc. (NOTV) saw a 36.61% increase in after-hours trading to $0.94, recovering from a 33.20% decline at the close, following preliminary Q4 revenue expectations of $137.5 million to $138.5 million and full-year revenue projections of $512.5 million to $513.5 million [2] - Applied Therapeutics, Inc. (APLT) rose 16.89% to $0.33 after a 30.19% gain at the close, with investors reacting positively to a narrower Q3 net loss of $19.0 million, or $0.13 per share, compared to a $68.6 million loss, or $0.48 per share, in the same quarter last year [3] - Alumis Inc. (ALMS) advanced 7.09% to $5.97, despite reporting a Q3 net loss of $110.8 million, wider than the $93.1 million loss in the prior year, with $2.1 million in collaboration income potentially boosting investor confidence [4] - TELA Bio, Inc. (TELA) increased 7.89% to $1.23 after a 14.08% gain at the close, reporting a reduced Q3 net loss of $8.6 million compared to $10.4 million a year earlier, with revenue growth of 9% to $20.7 million and revised 2025 guidance projecting at least 16% revenue growth over 2024 [5] - Corcept Therapeutics Inc. (CORT) gained 4.90% to $78.80, reflecting continued investor interest despite no specific news released [6] - BioRestorative Therapies, Inc. (BRTX) jumped 8.06% to $1.34, rebounding from a 6.77% decline at the close, following the announcement of a Type B meeting with the FDA to discuss a potential accelerated Biologics License Application pathway for its BRTX-100 program [7]

Revenue Performance - Revenue increased by $1.7 million, or 9%, from $19.0 million for the three months ended September 30, 2024, to $20.7 million for the same period in 2025[117]. - Revenue for the nine months ended September 30, 2025, was $59.4 million, an increase of $7.8 million, or 15%, from $51.7 million for the same period in 2024[117]. - Revenue increased by $1.7 million, or 9%, to $20.7 million for the three months ended September 30, 2025, driven by new customers and growing international sales[140]. - Revenue increased by $7.8 million, or 15%, to $59.4 million for the nine months ended September 30, 2025, compared to $51.7 million for the same period in 2024, driven by new customers and growing international sales[155]. Net Loss and Financial Position - The net loss decreased by $1.8 million, or 17%, from $10.4 million for the three months ended September 30, 2024, to $8.6 million for the same period in 2025[117]. - The company has an accumulated deficit of $388.5 million as of September 30, 2025, and expects to incur losses for the foreseeable future[119]. - Net loss for the nine months ended September 30, 2025, was $29.8 million, compared to a net loss of $28.6 million for the same period in 2024, reflecting a 4% increase in loss[167]. - As of September 30, 2025, cash and cash equivalents were $29.7 million, down from $52.7 million as of December 31, 2024[168]. - Cash used in operating activities was $23.3 million for the nine months ended September 30, 2025, an improvement from $34.1 million used in the same period in 2024[173]. Market Opportunity - The annual U.S. total addressable market opportunity for OviTex products is estimated to be approximately $1.8 billion[104]. - The annual U.S. current addressable market opportunity for OviTex PRS products is estimated to be approximately $800 million[109]. Product Development and Sales - The OviTex portfolio includes multiple configurations for various surgical procedures, with new product launches in 2023 and 2024 targeting specific hernia repair needs[105]. - Unit sales volume of OviTex increased by 22% to 5,795 units for the three months ended September 30, 2025, compared to 4,767 units in the same period of 2024[140]. - The company is focusing on research and development for new product variations and enhancements to extend the shelf life of existing products[116]. Expenses and Cost Management - Cost of revenue increased by $0.6 million, or 10%, to $6.6 million for the three months ended September 30, 2025, primarily due to higher product purchases[141]. - Gross profit increased by $1.1 million, or 9%, to $14.0 million for the three months ended September 30, 2025, attributed to increased unit sales and new customers[143]. - Sales and marketing expenses decreased by $1.2 million, or 8%, to $15.2 million for the three months ended September 30, 2025, due to lower compensation and benefits[146]. - General and administrative expenses increased by $0.3 million, or 7%, to $3.9 million for the three months ended September 30, 2025, primarily due to higher compensation and professional fees[147]. - Research and development expenses increased by $0.3 million, or 14%, to $2.3 million for the three months ended September 30, 2025, mainly due to higher study and development costs[148]. - Cost of revenue (excluding amortization of intangible assets) rose by $2.4 million, or 15%, to $18.5 million for the nine months ended September 30, 2025, primarily due to increased product purchases to support higher unit sales[156]. - Gross profit increased by $5.3 million, or 15%, to $40.6 million for the nine months ended September 30, 2025, attributed to higher unit sales and new customer additions[158]. - Sales and marketing expenses decreased by $2.0 million, or 4%, to $48.7 million for the nine months ended September 30, 2025, mainly due to lower compensation and benefits[161]. - General and administrative expenses increased by $0.8 million, or 7%, to $11.9 million for the nine months ended September 30, 2025, driven by higher professional fees and compensation[162]. - Research and development expenses rose by $0.3 million, or 5%, to $7.1 million for the nine months ended September 30, 2025, due to increased study costs[163]. Debt and Financing - The MidCap term loan matures on May 1, 2027, with an interest rate of 6.25% plus the greater of one-month Term SOFR or 1.0%[183]. - A debt refinancing transaction secured up to $70.0 million from Perceptive Advisors, with an initial loan of $60.0 million and an additional $10.0 million available upon meeting certain conditions[186]. - The new credit facility bears interest at a rate of 7.85% plus the greater of one-month Term SOFR or 4.25%, maturing on November 14, 2030[186]. - A 1% increase in interest rates would have resulted in a $0.3 million increase in interest expense for the nine months ended September 30, 2025[191]. - The company has made 36 monthly interest payments on the MidCap term loan since June 2022, with an extension of these payments elected in May 2025[183]. - The MidCap term loan has a prepayment fee of 1.0% and an exit fee of 5% at maturity or prepayment[184]. - As of September 30, 2025, there were no significant changes to the company's commitments and future minimum contractual obligations[185]. Risk Factors - The company is currently assessing the impact of the One Big Beautiful, Bill Act ("OBBBA") on its consolidated financial statements[152]. - The company does not currently have any material exposure to foreign currency fluctuations and does not engage in hedging activities[193]. - Inflationary factors may adversely affect operating results, although the company does not believe inflation has had a material impact to date[192]. - The company has established a redundant account at a high-credit-quality financial institution to mitigate liquidity risk following the events related to Silicon Valley Bank in 2023[189].

Core Insights - TELA Bio Inc reported mixed results for Q3, with losses of $0.19 per share, slightly better than the analyst consensus of $0.20 per share, but sales of $20.7 million fell short of the expected $21.788 million [1][2] Financial Performance - Quarterly losses were reported at $0.19 per share, beating the consensus estimate of $0.20 per share [1] - Quarterly sales amounted to $20.7 million, missing the analyst consensus estimate of $21.788 million [1] Management Commentary - CEO Antony Koblish highlighted continued growth and progress due to a strengthened leadership team and strategic changes in the commercial organization [2] Stock Offering - TELA Bio announced a $13.0 million underwritten registered direct offering of common stock and pre-funded warrants [2] Market Reaction - Following the earnings announcement, TELA Bio shares fell by 13.7%, trading at $0.96 [2] Analyst Ratings and Price Targets - Citizens analyst David Turkaly maintained a Market Outperform rating but lowered the price target from $7 to $5 [5] - Piper Sandler analyst Matt O'Brien reiterated a Neutral rating and reduced the price target from $2 to $1.25 [5]

Core Insights - TELA Bio Inc reported mixed results for Q3, with losses of 19 cents per share, slightly better than the analyst consensus of 20 cents per share, but sales of $20.700 million fell short of the expected $21.788 million [1][2] Financial Performance - Quarterly losses were reported at 19 cents per share, beating the consensus estimate of 20 cents per share [1] - Quarterly sales amounted to $20.700 million, missing the analyst consensus estimate of $21.788 million [1] Management Commentary - CEO Antony Koblish highlighted continued growth and progress due to a strengthened leadership team and strategic changes in the commercial organization [2] Stock Offering - TELA Bio announced a pricing of $13.0 million for an underwritten registered direct offering of common stock and pre-funded warrants [2] Market Reaction - Following the earnings announcement, TELA Bio shares fell by 13.7%, trading at $0.96 [2] Analyst Ratings and Price Targets - Citizens analyst David Turkaly maintained a Market Outperform rating but lowered the price target from $7 to $5 [5] - Piper Sandler analyst Matt O'Brien reiterated a Neutral rating and reduced the price target from $2 to $1.25 [5]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Company Performance - TELA Bio, Inc. reported a quarterly loss of $0.19 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.17, representing an earnings surprise of -11.76% [1] - The company posted revenues of $20.69 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 5.53%, but showing an increase from $18.96 million in the same quarter last year [2] - TELA Bio has not surpassed consensus EPS estimates over the last four quarters and has topped consensus revenue estimates only once during that period [2] Stock Performance - TELA Bio shares have declined approximately 62.3% since the beginning of the year, contrasting with the S&P 500's gain of 16.5% [3] - The current Zacks Rank for TELA Bio is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.15 on revenues of $24.8 million, and for the current fiscal year, it is -$0.79 on revenues of $85.4 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where TELA Bio operates, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was reported at $20.7 million, reflecting a 9% growth year-over-year, driven by stronger adoption and new accounts [4][14] - Gross margin remained stable at 68% for both Q3 2025 and Q3 2024, with gross profit increasing to $14 million from $12.9 million [14] - Net loss decreased to $8.6 million in Q3 2025 from $10.4 million in the prior year [16] Business Line Data and Key Metrics Changes - Revenue from OviTex grew by 6%, while OviTex PRS revenue increased by 12% compared to the prior year [14] - OviTex unit sales grew by 22% in Q3, while PRS unit sales saw a 3% increase [14] Market Data and Key Metrics Changes - International sales grew by 9%, with notable traction in the U.K. and early progress from the OviTex IHR launch in Europe [4] - The company expanded its market presence in the U.S. by adding 835 hospitals to its portfolio [9] Company Strategy and Development Direction - The company is focused on expanding its commercial footprint, improving operational discipline, and strengthening its patient-centric culture [4] - Investments in the sales organization are expected to enhance commercial performance moving forward [5] - The company aims to become a market leader in hernia and plastic reconstructive surgery through enhanced medical education and market access strategies [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving at least 16% revenue growth for the full year 2025 compared to 2024 [16] - For 2026, the company anticipates at least 15% revenue growth from 2025, with a focus on hiring and operational efficiency [17] Other Important Information - The company announced a refinancing and upsizing of its debt facility from $40 million to $60 million, along with a $13 million equity offering, adding approximately $26 million in net cash [18] - The company has surpassed 100,000 implantations of OviTex and OviTex PRS globally, indicating strong market impact [7] Q&A Session Summary Question: Rationale for debt refinancing and equity raise - Management feels comfortable with the cash runway, stating the refinancing was proactive to avoid future amortization issues and to secure additional capital [25] Question: Guidance for 2025 and 2026 growth expectations - The company provided a conservative growth estimate for 2025, factoring in hiring and operational adjustments, with a goal of at least 15% growth for 2026 [26][27] Question: Details on Salesforce hiring - The company aims to increase its Salesforce to over 90 territory managers by Q1 2026, with a focus on hiring high-caliber talent [31][34] Question: Break-even profile - Management continues to target a break-even point in the high $20 million range per quarter, emphasizing operational efficiency [36] Question: Q4 growth expectations - The company expects at least 16% year-over-year growth in Q4, with potential upside from recent hiring and organizational improvements [46]

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Core Viewpoint - TELA Bio, Inc. has announced a registered direct offering of common stock and pre-funded warrants, aiming to raise approximately $13.0 million for various corporate purposes [1][2]. Group 1: Offering Details - The offering consists of 4,189,000 shares of common stock priced at $1.11 per share and pre-funded warrants for 7,523,000 shares at $1.1099 each [1]. - The gross proceeds from the offering are expected to be around $13.0 million, assuming no exercise of the pre-funded warrants [1]. - The offering is anticipated to close on or about November 17, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - TELA intends to utilize the net proceeds for general corporate purposes, including sales and marketing, research and development, general and administrative expenses, working capital, and capital expenditures [2]. Group 3: Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions that prioritize the preservation and restoration of the patient's anatomy [5]. - The company aims to provide advanced and economically effective solutions that leverage the patient's natural healing response while minimizing long-term exposure to synthetic materials [5].